INDV Share Price Performance
US$40.51
23.70 (140.99%)
30.5% undervalued intrinsic discount
US$58.33
Fair Value
Price US$40.51
AnalystHighTarget US$58.33
AnalystConsensusTarget US$50.83
Fair ValueUS$58.33
Share Pricen/a
Narrative Update • Jul 10
Indivior Pharmaceuticals, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
INDV Community Narratives
AN
Fair Value
·Fair Value US$58.33 30.5% undervalued intrinsic discount
Long Acting Injectables And Cost Discipline Will Transform This Addiction Treatment Leader
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$50.83 20.3% undervalued intrinsic discount
Long Acting Injectable Therapies Will Drive Margin Expansion And Support Long Term Recovery Solutions
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Long Acting Injectable Therapies Will Drive Margin Expansion And Support Long Term Recovery Solutions
Indivior is betting that more patients will switch to long‑lasting injectable treatment for opioid addiction, helped by easier use and a new awareness campaign that could keep people on therapy longer. The big question is whether cost cuts and a shift toward better‑paying customers can turn that momentum into stronger profits—or whether expectations are already too optimistic.Read more
AN
US$50.83
20.3% undervalued intrinsic discount
Fair Value
Revenue
2.31% p.a.
Profit Margin
36.85%
Future PE
13.86x
Price in 2029
US$62.04
Long Acting Injectables And Cost Discipline Will Transform This Addiction Treatment Leader
Indivior is doubling down on its long-acting addiction shot, betting that easier dosing, wider insurance coverage, and a new awareness push can bring more people into treatment. At the same time, a hard cost-cutting plan could lift profits—but it risks slowing growth if the business gets too lean or if adoption doesn’t expand as hoped.Read more
AN
US$58.33
30.5% undervalued intrinsic discount
Fair Value
Revenue
4.02% p.a.
Profit Margin
40.59%
Future PE
13.74x
Price in 2029
US$71.19
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
INDV: Turnaround Plan And Index Additions Will Drive Earnings Momentum
Fair Value: US$50.83 20.3% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
INDV: Raised Guidance And Buybacks Will Support A Turnaround Repricing
Fair Value: US$58.33 30.5% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Indivior Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- 2.07
- 84.96%
- 19.53%
- -337.5%
About INDV
- Founded
- 2014
- Employees
- 833
- CEO
- WebsiteView website
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Recent INDV News & Updates
Narrative Update • Jun 26
